Daily Cardiology Research Analysis
Three high-impact cardiology studies advance clinical practice: an RCT shows FFR-guided complete revascularization in NSTEMI reduces 1-year adverse events; a cluster RCT demonstrates inpatient influenza vaccination after acute heart failure reduces death/readmission; and an IPD meta-analysis confirms β-blockers benefit post-MI patients with mildly reduced EF (40–49%). These findings refine invasive strategy, broaden preventive vaccination in cardiology, and clarify secondary prevention pharmacot
Summary
Three high-impact cardiology studies advance clinical practice: an RCT shows FFR-guided complete revascularization in NSTEMI reduces 1-year adverse events; a cluster RCT demonstrates inpatient influenza vaccination after acute heart failure reduces death/readmission; and an IPD meta-analysis confirms β-blockers benefit post-MI patients with mildly reduced EF (40–49%). These findings refine invasive strategy, broaden preventive vaccination in cardiology, and clarify secondary prevention pharmacotherapy.
Research Themes
- Physiology-guided complete revascularization in NSTEMI
- Vaccination as cardioprotective strategy in heart failure
- Secondary prevention after MI with mildly reduced ejection fraction
Selected Articles
1. Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial.
In this multicenter RCT of NSTEMI with multivessel disease (n=478), FFR-guided complete revascularization during the index procedure reduced the 1-year composite of all-cause death, nonfatal MI, any revascularization, and stroke vs culprit-only PCI (5.5% vs 13.6%; HR 0.38). Benefits were mainly driven by fewer repeat revascularizations and lower NACE; other secondary outcomes were similar.
Impact: This trial provides high-level evidence to favor physiology-guided complete revascularization in NSTEMI with multivessel disease, a frequent and clinically relevant scenario.
Clinical Implications: Consider FFR-guided complete revascularization at index PCI for NSTEMI with multivessel disease to reduce 1-year adverse events, particularly repeat revascularization, when anatomy and clinical status permit.
Key Findings
- Primary composite endpoint at 1 year: 5.5% (complete) vs 13.6% (culprit-only); HR 0.38 (95% CI 0.20–0.72), p=0.003
- Lower any revascularization: 3.0% vs 11.5%; HR 0.24 (95% CI 0.11–0.56), p<0.001
- Lower net adverse clinical events (NACE): 6.3% vs 15.3%; HR 0.39 (95% CI 0.21–0.70), p=0.002
Methodological Strengths
- Prospective multicenter randomized design with predefined primary endpoint
- Physiology guidance (FFR) and clinical follow-up to 1 year
Limitations
- Modest sample size; primary benefit driven by fewer revascularizations rather than mortality
- Open-label design; operator blinding not feasible; generalizability beyond trial centers uncertain
Future Directions: Larger trials powered for hard outcomes (death/MI) and cost-effectiveness analyses of FFR-guided complete revascularization in NSTEMI are warranted.
IMPORTANCE: The benefits of fractional flow reserve (FFR)-guided complete coronary revascularization in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain unclear. OBJECTIVE: To compare FFR-guided complete revascularization of nonculprit lesions vs culprit-only revascularization in patients with NSTEMI and multivessel disease. DESIGN, SETTING, AND PARTICIPANTS: This prospective, investigator-initiated, multicenter, international randomized clinical trial was conducted at 9 hospitals in Europe. Patients with NSTEMI and multivessel disease who had successful revascularization of the culprit lesion were enrolled between June 2018 and July 2024, and final follow-up was completed on July 21, 2025. The analysis was conducted on July 28, 2025. Eligibility criteria included the presence of at least 1 stenosis of at least 50% in a nonculprit lesion amen...
2. Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
In this pragmatic cluster-randomized trial across 164 hospitals (n=7771), offering free influenza vaccination before discharge to patients admitted with acute heart failure reduced the 12-month composite of all-cause mortality or any readmission (41.2% vs 47.0%; OR 0.83; p=0.019) and serious adverse events. The strategy was feasible and scalable within routine inpatient care.
Impact: Provides robust randomized evidence that inpatient influenza vaccination improves outcomes after acute heart failure, supporting policy-level integration of vaccination into cardiovascular care.
Clinical Implications: Implement standing inpatient vaccination programs for acute HF admissions before discharge to reduce 12-month mortality/readmission, especially in low-uptake settings.
Key Findings
- Primary outcome (12-month all-cause mortality or any readmission): 41.2% vs 47.0%; OR 0.83 (95% CI 0.72–0.97); p=0.019
- Serious adverse events lower with vaccination: OR 0.82 (95% CI 0.70–0.96); p=0.013
- Large multicenter, multiseason, cluster design with point-of-care vaccination feasibility
Methodological Strengths
- Pragmatic multiregional cluster-randomized controlled design over three seasons
- Large sample size with standardized follow-up and hierarchical modeling
Limitations
- Cluster design may introduce imbalance; potential contamination and varying vaccine uptake
- Generalizability outside China requires validation; composite excludes early events in some strata
Future Directions: Replication in diverse health systems and evaluation of different vaccine strategies (eg, high-dose, adjuvanted) and cost-effectiveness analyses are needed.
BACKGROUND: Influenza vaccination is widely recommended to prevent death and serious illness in vulnerable people, including those with heart failure. However, the randomised evidence to support this practice is limited and few people are vaccinated in many parts of the world. We aimed to determine whether influenza vaccination can improve the outcome of patients after an episode of acute heart failure requiring admission to hospital in China. METHODS: We undertook a pragmatic, multiregional, parallel-group, cluster (hospital)-randomised, controlled, superiority trial over three winter seasons in China. Participating hospitals were located in the counties of 12 provinces with the capability of establishing a point-of-care service to provide free influenza vaccination to a sufficient number of patients before their discharge, if allocated to the intervention group. No such service was used in hospitals allocated to usual care (control) but patients were informed of fee-for-service influenza vaccina...
3. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
This IPD meta-analysis of 4 randomized trials (n=1885) showed that β-blockers initiated within 14 days post-MI in patients with LVEF 40–49% without heart failure reduced the composite of all-cause death, new MI, or heart failure (HR 0.75; p=0.031). Endpoints were independently adjudicated with no heterogeneity detected.
Impact: Clarifies β-blocker benefit in the gray zone of mildly reduced EF after MI, filling a key evidence gap and potentially informing guideline recommendations.
Clinical Implications: For post-MI patients with LVEF 40–49% and no heart failure, long-term oral β-blocker therapy should be considered to reduce death/MI/HF risk, alongside standard secondary prevention.
Key Findings
- Primary composite of all-cause death, new MI, or heart failure reduced with β-blockers: HR 0.75 (95% CI 0.58–0.97); p=0.031
- Randomization within 14 days post-MI; median follow-up >1 year; endpoints independently adjudicated
- No heterogeneity across the four trials
Methodological Strengths
- Individual patient-level meta-analysis of randomized trials with prespecified outcomes
- Independent endpoint adjudication and fixed-effects one-stage Cox modeling
Limitations
- Subgroup from trials not individually powered for LVEF 40–49%; possible residual confounding within trial protocols
- Applicability beyond 40–49% EF or in patients with HF signs remains uncertain
Future Directions: Prospective RCTs specifically powered in LVEF 40–49% and mechanistic studies to define responders and optimal dosing are warranted.
BACKGROUND: The effects of β-blocker therapy on clinical outcomes in patients with myocardial infarction and mildly reduced (40-49%) left ventricular ejection fraction (LVEF) are largely unknown. Four recently conducted randomised trials tested the efficacy of β blockers after a recent myocardial infarction in patients without reduced LVEF (LVEF ≥40%). However, none were individually powered to assess these effects in the subgroup of patients with mildly reduced LVEF. We aimed to assess the efficacy of β blockers in patients with myocardial infarction and mildly reduced LVEF during the index hospitalisation. METHODS: We conducted an individual patient-level meta-analysis of patients with mildly reduced LVEF and no history or signs of heart failure from four recent clinical trials. These studies were included because they were randomised controlled trials testing long-term effects (median follow-up >1 year) of oral β-blocker therapy in patients who recently had a myocardial infarction (randomisation within 14 days) and had mildly reduced LVEF. No further studies were found in a systematic review (Jan 1, 2020 to June 26, 2025). A one-stage, fixed-effects, Cox proportional hazards regression model was used to assess the treatment effect of β blockers on the predefined primary composite endpoint of all-cause death, new myocardial infarction, or heart failure. All endpoints were independently adjudicated. This meta-analysis was registered with PROSPERO (CRD420251023480). FINDINGS: 1885 patients with myocardial infarction and mildly reduced LVEF were included...